Economy

Bausch Health, formerly Valeant, predicts revenue growth as debt load lessens

Bausch Health's "significant seven" major products include eye care products that treat conditions ranging from glaucoma to bloodshot eyes.Mike Mergen/Bloomberg News

The CEO of Bausch Health Companies Inc. is predicting revenue growth this year as the drugmaker emerges from a mountain of debt and lawsuits.

Joseph Papa said Monday he expects Bausch — formerly known as Valeant Pharmaceuticals —will double revenue from its seven major products to between US$150 million and US$300 million, driving overall sales growth.

The so-called “significant seven” include eye care products that treat conditions ranging from glaucoma to bloodshot eyes.

Leave a Reply

Your email address will not be published. Required fields are marked *